Investor Presentation
Investor Presentation
Melbourne, April 27, 2017 AEST (ABN Newswire) - Bluechiip Ltd (ASX:BCT) is pleased to provide the Company's latest Investor Presentation.

Bluechiip Highlights

- Highly differentiated, expanding, protected core technology

- Chasing immediate, addressable market of US$250 million + from 3 recently executed licence and supply agreements

o Genea Biomedx - IVF Market (US$20M) with upcoming product launch through Merck
o Planet Innovation - Cryopreservation, transport and life sciences (US$30M) market opportunities
o Labcon North America - Biopreservation market (US$200M) with initial 2ml vial market ($40M)

- Growing target bio-preservation market (>US$2B) & very large adjacent markets

- Dramatically increasing partner pipeline with well advanced product development

- Growing initial repeat licence, service and product revenues

- Expected significant revenue growth in FY'18 on partner's product launch

To view the full presentation, please visit:
http://abnnewswire.net/lnk/2Y01PE9J


About Bluechiip Ltd

Bluechiip Ltd ASX BCTBluechiip Ltd (ASX:BCT) has developed a wireless tracking solution for the healthcare and life science, security, defence and manufacturing industries which represents a generational change from current methods such as labels (hand-written and pre-printed), barcodes (linear and 2D) and microelectronic integrated circuit (IC)-based RFID (Radio Frequency Identification).

The unique tag is based on MEMS technology and contains no electronics. The tag can either be embedded or manufactured into a storage product, such as vials or bags. Easy identification, along with any associated information from the tag such as temperature can be detected by a reader, which can also sense the temperature of the tagged items. The traditional identification technologies have significant limitations. Whereas a barcode requires a visible tag or line-of-sight optical scan, bluechiip(R) technology does not. Unlike labels, barcodes and RFID, the bluechiip(R) technology can sense the temperature of each item a tag is attached to, or embedded in.

The bluechiip(R) technology has initial applications in the healthcare industry particularly those businesses which require cryogenic storage facilities (biobanks and biorepositories). bluechiip(R) offers the only technology that enables accurate and reliable tracking of products including stem cells, cord blood, and other biospecimens. In addition to functioning in extreme temperatures, the bluechiip(R) tracking solution can survive autoclaving, gamma irradiation sterilization, humidification, centrifuging, cryogenic storage and frosting.

The bluechiip(R) technology has other healthcare applications in pathology, clinical trials and forensics. Several other key markets outside of healthcare include cold-chain logistics/supply chain, security/defence, industrial/manufacturing and aerospace/aviation.

Further information is available at http://www.bluechiip.com

    


Contact

Andrew McLellan
Managing Director & CEO
Bluechiip Limited
Tel: +61-3-9763-9763
Mob: +61-457-823-470
Email: andrew.mclellan@bluechiip.com
www.bluechiip.com



Related Companies

Bluechiip Ltd

ABN Newswire This Page Viewed:  (Last 7 Days: 10) (Last 30 Days: 34) (Since Published: 1508) 
ANALYTICS: LOGIN HERE

Bluechiip Ltd NEWS: RECENT VISITS (4400)

Research Report

Social Media